European regulators’ CHMP endorsed Moderna’s mCombriax (mRNA‑1083), a combined influenza and COVID‑19 mRNA vaccine, recommending approval for older adults. The CHMP opinion paves the way for European Commission authorization and would make mCombriax one of the first combination respiratory mRNA vaccines on the market. Moderna CEO Stéphane Bancel said the recommendation marks an important milestone after regulatory setbacks in the U.S.; Moderna had withdrawn and then resubmitted parts of the dossier following FDA queries. Combination vaccines place two antigens into a single formulation—regulators focus on both component efficacy and interaction effects.